Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury

Stock Information for Oragenics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Oragenics Inc.

Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation
ORAGENICS FILES ANNUAL REPORT ON FORM 10-K
ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION
ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION
Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia
Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy
Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program
Oragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient Care

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.